241 related articles for article (PubMed ID: 32133901)
1. Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults.
Buckley MS; Agarwal SK; Garcia-Orr R; Saggar R; MacLaren R
J Intensive Care Med; 2021 Apr; 36(4):466-476. PubMed ID: 32133901
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2 different inhaled epoprostenol dosing strategies for acute respiratory distress syndrome in critically ill adults: Weight-based vs fixed-dose administration.
Buckley MS; Mendez A; Radosevich JJ; Agarwal SK; MacLaren R
Am J Health Syst Pharm; 2023 Feb; 80(Suppl 1):S11-S22. PubMed ID: 35877207
[TBL] [Abstract][Full Text] [Related]
3. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients.
Torbic H; Szumita PM; Anger KE; Nuccio P; LaGambina S; Weinhouse G
J Crit Care; 2013 Oct; 28(5):844-8. PubMed ID: 23683572
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary Hypertension Following Cardiac Surgery.
McGinn K; Reichert M
Ann Pharmacother; 2016 Jan; 50(1):22-6. PubMed ID: 26438636
[TBL] [Abstract][Full Text] [Related]
5. The role of inhaled prostacyclin in treating acute respiratory distress syndrome.
Searcy RJ; Morales JR; Ferreira JA; Johnson DW
Ther Adv Respir Dis; 2015 Dec; 9(6):302-12. PubMed ID: 26294418
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide versus epoprostenol for refractory hypoxemia in Covid-19.
Poonam PBH; Koscik R; Nguyen T; Rikhi S; Lin HM
PLoS One; 2022; 17(6):e0270646. PubMed ID: 35759496
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study.
Al Sulaiman K; Korayem GB; Altebainawi AF; Al Harbi S; Alissa A; Alharthi A; Kensara R; Alfahed A; Vishwakarma R; Al Haji H; Almohaimid N; Al Zumai O; Alrubayan F; Asiri A; Alkahtani N; Alolayan A; Alsohimi S; Melibari N; Almagthali A; Aljahdali S; Alenazi AA; Alsaeedi AS; Al Ghamdi G; Al Faris O; Alqahtani J; Al Qahtani J; Alshammari KA; Alshammari KI; Aljuhani O
Crit Care; 2022 Oct; 26(1):304. PubMed ID: 36192801
[TBL] [Abstract][Full Text] [Related]
8. Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant: A Randomized Clinical Trial.
Ghadimi K; Cappiello J; Cooter-Wright M; Haney JC; Reynolds JM; Bottiger BA; Klapper JA; Levy JH; Hartwig MG;
JAMA Surg; 2022 Jan; 157(1):e215856. PubMed ID: 34787647
[TBL] [Abstract][Full Text] [Related]
9. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults.
Gebistorf F; Karam O; Wetterslev J; Afshari A
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD002787. PubMed ID: 27347773
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Continuous Inhaled Epoprostenol in the Treatment of Acute Respiratory Distress Syndrome, Including Patients With SARS-CoV-2 Infection.
Niss HL; Mohamed A; Berry TP; Saettele TM; Haines MM; Thomas EL
Ann Pharmacother; 2022 Oct; 56(10):1093-1099. PubMed ID: 35021923
[TBL] [Abstract][Full Text] [Related]
11. A Narrative Review on the Administration of Inhaled Prostaglandins in Critically Ill Adult Patients With Acute Respiratory Distress Syndrome.
Ware LR; Kim CS; Szumita PM; DeGrado JR
Ann Pharmacother; 2024 May; 58(5):533-548. PubMed ID: 37589097
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Inhaled Epoprostenol in Patients With Acute Respiratory Distress Syndrome and COVID-19-Associated Acute Respiratory Distress Syndrome.
Robinson J; Santarelli A; Wilks N; Latu L; Charran O; Lalitsasivimol D; Dietrich T; Ashurst J
Cureus; 2022 Aug; 14(8):e28274. PubMed ID: 36158384
[TBL] [Abstract][Full Text] [Related]
13. Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
Ghadimi K; Cappiello JL; Wright MC; Levy JH; Bryner BS; DeVore AD; Schroder JN; Patel CB; Rajagopal S; Shah SH; Milano CA;
Circulation; 2023 Oct; 148(17):1316-1329. PubMed ID: 37401479
[TBL] [Abstract][Full Text] [Related]
14. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults.
Afshari A; Brok J; Møller AM; Wetterslev J
Cochrane Database Syst Rev; 2010 Jul; (7):CD002787. PubMed ID: 20614430
[TBL] [Abstract][Full Text] [Related]
15. Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome.
Albert M; Corsilli D; Williamson DR; Brosseau M; Bellemare P; Delisle S; Nguyen AQ; Varin F
World J Crit Care Med; 2017 Feb; 6(1):74-78. PubMed ID: 28224110
[TBL] [Abstract][Full Text] [Related]
16. Inhaled pulmonary vasodilators are not associated with improved gas exchange in mechanically ventilated patients with COVID-19: A retrospective cohort study.
Lubinsky AS; Brosnahan SB; Lehr A; Elnadoury O; Hagedorn J; Garimella B; Bender MT; Amoroso N; Artigas A; Bos LDJ; Kaufman D
J Crit Care; 2022 Jun; 69():153990. PubMed ID: 35180636
[TBL] [Abstract][Full Text] [Related]
17. Acute and sustained effects of early administration of inhaled nitric oxide to children with acute respiratory distress syndrome.
Fioretto JR; de Moraes MA; Bonatto RC; Ricchetti SM; Carpi MF
Pediatr Crit Care Med; 2004 Sep; 5(5):469-74. PubMed ID: 15329164
[TBL] [Abstract][Full Text] [Related]
18. In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients.
Li J; Augustynovich AE; Gurnani PK; Fink JB
Respir Res; 2021 Aug; 22(1):231. PubMed ID: 34419068
[TBL] [Abstract][Full Text] [Related]
19. The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary Due To COVID-19: a Case Series.
Imtiaz K; Jodeh W; Sudekum D; DiGiovine B; Hecht J
J Crit Care Med (Targu Mures); 2022 Jan; 8(1):33-40. PubMed ID: 35274053
[TBL] [Abstract][Full Text] [Related]
20. Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: A quality improvement project.
Davis SL; Crow JR; Fan JR; Mattare K; Whitman G; Brower RG; Rowden A; Pustavoitau A
Am J Health Syst Pharm; 2019 Sep; 76(18):1413-1419. PubMed ID: 31372630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
